Survivin as a biological biomarker for diagnosis and therapy

References

• Ambrosini G, Adida C, Altieri DC., A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–921.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin - The inconvenient IAP. Semin Cell Dev Biol. 2015;39:91–96.
   PubMed Web of Science ®Google Scholar
• Nogueira-Ferreira R, Vitorino R, J Ferreira-Pinto M, et al. Exploring the role of post-translational modifications on protein-protein interactions with survivin. Arch Biochem Biophys. 2013;538(2):64–70.
   PubMed Web of Science ®Google Scholar
• Hu F, P.d., Zheng W, et al. Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle, apoptosis and autophagy of cancer cells. Oncotarget. 2017;8(69):113687–113700.
   PubMedGoogle Scholar
• Silke J, Vaux DL. IAP gene deletion and conditional knockout models. Semin Cell Dev Biol. 2015;39:97–105.
   PubMed Web of Science ®Google Scholar
• Qp V. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005;310(5753):1499–1504.
   PubMed Web of Science ®Google Scholar
• Gullulu O, Hehlgans S, E Mayer B, et al. A spatial and functional interaction of a heterotetramer Survivin-DNA-PKcs complex in DNA damage response. Cancer Res. 2021. DOI:https://doi.org/10.1158/0008-5472.CAN-20-2931.
   Google Scholar
• Hu S, Qu Y, Xu X, et al. Nuclear survivin and its relationship to DNA damage repair genes in non-small cell lung cancer investigated using tissue array. PLoS One. 2013;8(9):e74161.
   PubMed Web of Science ®Google Scholar
• Ju L, Zhang X, Deng Y, et al. Enhanced expression of Survivin has distinct roles in adipocyte homeostasis. Cell Death Dis. 2017;8(1):e2533.
   PubMedGoogle Scholar
• Conde M, Susanne Michen, Ralf Wiedemuth, et al. Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells. BMC Cancer. 2017;17(1):889.
   PubMedGoogle Scholar
• Adamopoulos PG, Tsiakanikas P, Adam EE, et al. Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. Genomics. 2021;113(1 Pt 2):573–581.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang J, Li F. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res. 2006;25(3):391–402.
   PubMed Web of Science ®Google Scholar
• Chen X, Duan N, Zhang C, et al. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer. 2016;7(3):314–323.
   PubMed Web of Science ®Google Scholar
• Chu Y, Yao PY, Wang W, et al. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol. 2011;3(4):260–267.
   PubMed Web of Science ®Google Scholar
• Paul A, Krelin Y, Arif T, et al. A new role for the mitochondrial pro-apoptotic PROTEIN SMAC/diablo in phospholipid synthesis associated with tumorigenesis. Mol Ther. 2018;26(3):680–694.
   PubMed Web of Science ®Google Scholar
• Du C, M.f., Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c–dependent caspase activation by eliminating IAP Inhibition. Cell. 2000;102(1):33–42.
   PubMed Web of Science ®Google Scholar
• Khan Z, Khan AA, Yadav H, et al. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett. 2017;22(1):8.
   PubMedGoogle Scholar
• Dharmapatni AA, Smith MD, Findlay DM, et al. Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther. 2009;11(1):R13.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Lopez-Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer. 2011;10(1):35.
   PubMedGoogle Scholar
• Venkatesan N, Kanwar JR, Deepa PR, et al. Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma. Chem Biol Interact. 2016;252:141–149.
   PubMed Web of Science ®Google Scholar
• Khan S, Aspe JR, Asumen MG, et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer. 2009;100(7):1073–1086.
   PubMed Web of Science ®Google Scholar
• Fukuda S, L.m.p. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors implication of survivin expression in normal hematopoiesis. Blood. 2001;98(7):2091–2100.
   PubMed Web of Science ®Google Scholar
• Leung CG, Xu Y, Mularski B, et al. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med. 2007;204(7):1603–1611.
   PubMed Web of Science ®Google Scholar
• Andersson SE, N D Svensson M, C Erlandsson M, et al. Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 2012;7(10):e47668.
   PubMed Web of Science ®Google Scholar
• Pratibha Singh JH, Peirong H, Speth JM, et al. Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells. Blood. 2012;119(7)(7):1671–1682.
   Web of Science ®Google Scholar
• Cohran V, Managlia E, M Bradford E, et al. Epithelial PIK3R1 (p85) and TP53 regulate survivin expression during adaptation to ileocecal resection. Am J Pathol. 2016;186(7):1837–1846.
   PubMed Web of Science ®Google Scholar
• Tamm I, Y.w, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315–5320.
   PubMed Web of Science ®Google Scholar
• Xiaoyu J, Shanshan G, Yongbo Q, et al. Effects of poly(I:C) and MF59 co-adjuvants on immunogenicity and efficacy of survivin polypeptide immunogen against melanoma. J Cell Physiol. 2018;233(6):4926–4934.
   PubMed Web of Science ®Google Scholar
• Mishra H, Kumar Mishra P, Ekielski A, et al. Functionalized nanoliposomes loaded with anti survivin and anti angiogenic agents to enhance the activity of chemotherapy against melanoma by 4-pronged action. Med Hypotheses. 2018;116:141–146.
   PubMed Web of Science ®Google Scholar
• Michael Samarkos GP, Athanasoula K, Benopoulou Ο, et al. Significance of survivin mRNA blood levels in patients with melanoma. J BUON. 2018;23(7):96–103.
   PubMedGoogle Scholar
• Bastea LI, Hollant LMA, Döppler HR, et al. Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death. Sci Rep. 2019;9(1):16588.
   PubMedGoogle Scholar
• Brown M, Zhang W, Yan D, et al. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. PLoS One. 2020;15(1):e0226917.
   PubMed Web of Science ®Google Scholar
• Heidari Z, Sagheb HM, Hakimi A, et al. Evaluation of immunohistochemical expression of survivin and its correlation with −31G/C gene polymorphism in colorectal cancer. Med Mol Morphol. 2019;52(2):82–89.
   PubMed Web of Science ®Google Scholar
• Qianwen Shao JX, Deng R, Wei W, et al. The expressions of YAP1, β-catenin and survivin in colon cancer tissues and their clinical significance. Int J Clin Exp Pathol. 2018;11(12):6032–6038.
   PubMed Web of Science ®Google Scholar
• Tianyi Y, Hongwen Y, Yang X, et al. Role of Smac, survivin, XIAP, and Omi/HtrA2 proteins in determining the chemotherapeutic response of patients with cervical cancer treated with neoadjuvant chemotherapy. Cancer Biomark. 2019;26(3):249–259.
   PubMed Web of Science ®Google Scholar
• Yu M, Xu B, Yang H, et al. <p>MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin. Cancer Manag Res. 2019;11:6511–6519.
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia D, Pérez-Hernández M, Korrodi-Gregório L, et al. The natural-based antitumor compound T21 decreases survivin levels through potent STAT3 inhibition in lung cancer models. Biomolecules. 2019;9(8):361.
   Web of Science ®Google Scholar
• Nitschkowski D, Marwitz S, Kotanidou SA, et al. Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy. Clin Epigenetics. 2019;11(1):157.
   PubMed Web of Science ®Google Scholar
• Krafft U, Tschirdewahn S, Hess J, et al. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urol Oncol. 2019;37(11):810 e7–810 e15.
   Web of Science ®Google Scholar
• Stec R, Cierniak S, Lubas A, et al. Intensity of nuclear staining for Ki-67, p53 and survivin as a new prognostic factor in non-muscle invasive bladder cancer. Pathol Oncol Res. 2020;26(2)(2):1211–1219.
   Web of Science ®Google Scholar
• Zhang Y, Wang J, Sui X, et al. Prognostic and clinicopathological value of survivin in diffuse large b-cell lymphoma: a meta-analysis. Medicine (Baltimore). 2015;94(36):e1432.
   PubMed Web of Science ®Google Scholar
• Hong JY, Chaehwa Park KJR, Hong M, et al. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget. 2017;8(8):13782–13791.
   PubMedGoogle Scholar
• Hong L, Yanning Tian CD, Xiang L, et al. Knockdown of Diacylglycerol Kinase Zeta (DGKZ) Induces Apoptosis and G2M Phase Arrest in Human Acute Myeloid Leukemia HL-60 Cells Through MAPKsurvivincaspase Pathway. Pharmazie. 2019;74:418–422.
   PubMed Web of Science ®Google Scholar
• Huang J, Lyu H, Wang J, et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett. 2015;366(2):160–172.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang C, Song Y, et al. Prognostic role of survivin in patients with glioma. Medicine (Baltimore). 2018;97(17):e0571.
   PubMed Web of Science ®Google Scholar
• Sha L, Yue Meng LW, Chang Y, et al. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients. Oncotarget. 2017;8(25):41282–41293.
   PubMedGoogle Scholar
• Veiga GLD, Silva RDMD, Pereira EC, et al. The role of Survivin as a biomarker and potential prognostic factor for breast cancer. Rev Assoc Med Bras. 2019;65(6):893–901. 1992.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yan H, Li R, et al. High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin. Medicine (Baltimore). 2019;98(20):e15607.
   PubMed Web of Science ®Google Scholar
• Zareifar S, Ghorbani S, Monabbati A, et al. Expression of antiapoptotic proteins livin and survivin in pediatric AML patients, as prognostic markers. Pediatr Hematol Oncol. 2018;35(4):250–256.
   PubMed Web of Science ®Google Scholar
• Salman T, Argon A, Kebat T, et al. The prognostic significance of survivin expression in gallbladder carcinoma. APMIS. 2016;124(8):633–638.
   PubMed Web of Science ®Google Scholar
• Xiong C, Liu H, Chen Z, et al. Prognostic role of survivin in renal cell carcinoma: a system review and meta-analysis. Eur J Intern Med. 2016;33:102–107.
   PubMed Web of Science ®Google Scholar
• Faccion RS, Bernardo PS, Faria de Lopes GP, et al. p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors. Cell Oncol (Dordr). 2018;41(2):141–157.
   PubMed Web of Science ®Google Scholar
• Morgia G, Micali A, Rinaldi M, et al. Survivin and NAIP in human benign prostatic hyperplasia: protective role of the association of serenoa repens, lycopene and selenium from the randomized clinical study. Int J Mol Sci. 2017;18(3):680.
   Web of Science ®Google Scholar
• Gokmen Karasu AF, Sonmez FC, Aydin S, et al. Survivin expression in simple endometrial polyps and tamoxifen-associated endometrial polyps. Int J Gynecol Pathol. 2018;37(1):27–31.
   PubMed Web of Science ®Google Scholar
• Jourabchin A, Mazoochi T, Haddad Kashani H, et al. Assessment of relationship between expression of survivin protein and histopathology diagnosis and malignancy severity in colon specimen. J Gastrointest Cancer. 2020;51(1):76–82.
   PubMed Web of Science ®Google Scholar
• Kushitani K, Amatya VJ, Mawas AS, et al. Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia. Oncol Lett. 2018;15(3):3540–3547.
   PubMed Web of Science ®Google Scholar
• Zhou XL, Wang M. Expression levels of survivin, Bcl-2, and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res. 2015;14(4):17059170.
   Web of Science ®Google Scholar
• Siddharth S, Das S, Nayak A, et al. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis. Clin Exp Metastasis. 2016;33(7):661–675.
   PubMed Web of Science ®Google Scholar
• Kogo R, How C, Chaudary N, et al. The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer. Oncotarget. 2015;6(2):1090–1100.
   PubMedGoogle Scholar
• Sonja Selemetjev SS, Paunovic I, Tatic S, et al. Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma. J Cancer Res Ther. 2018;14(8):114–119.
   Google Scholar
• Ahn JK, Oh J-M, Lee J, et al. Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation. 2010;33(6):381–388.
   PubMed Web of Science ®Google Scholar
• Smith MD, Weedon H, Papangelis V, et al. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford). 2010;49(5):862–875.
   PubMed Web of Science ®Google Scholar
• Kusner LL, Ciesielski MJ, Marx A, et al. Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One. 2014;9(7):e102231.
   PubMed Web of Science ®Google Scholar
• Sharief MK, Y.k.s. Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol. 2001;119(2):358–364.
   PubMed Web of Science ®Google Scholar
• Legorreta-Haquet MV, Flores-Fernández R, Blanco-Favela F, et al. Prolactin levels correlate with abnormal B cell maturation in MRL and MRL/lpr mouse models of systemic lupus erythematosus-like disease. Clin Dev Immunol. 2013;2013:287469.
   PubMedGoogle Scholar
• Ebrahimiyan H, Aslani S, Rezaei N, et al. Survivin and autoimmunity; the ins and outs. Immunol Lett. 2018;193:14–24.
   PubMed Web of Science ®Google Scholar
• Koike Y, Muroi E, Yoshizaki A, et al. Autoantibody against survivin in patients with systemic sclerosis. J Rheumatol. 2010;37(9):1864–1870.
   PubMed Web of Science ®Google Scholar
• Erlandsson MC, Turkkila M, Pullerits R, et al. Survivin measurement improves clinical prediction of transition from arthralgia to RA-biomarkers to improve clinical sensitivity of transition from arthralgia to RA. Front Med (Lausanne). 2018;5:219.
   PubMed Web of Science ®Google Scholar
• Xiaozhen Liu CF, Liu J, Jian L, et al. The importance of EGFR as a biomarker in molecular apocrine breast cancer. Hum Pathol. 2018;11:1–10.
   Google Scholar
• Morales-Gutierrez C, Abad-Barahona A, Moreno-González E, et al. Tumour VEGF/non tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients. Eur J Surg Oncol. 2011;37(6):526–531.
   PubMed Web of Science ®Google Scholar
• Arrate Sevilla MCM, Ezkurra PA, Rasero J, et al. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma. PLoS One. 2020;15(3):e0230136.
   Google Scholar
• Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–168.
   PubMed Web of Science ®Google Scholar
• Acimovic M, et al. Survivin and VEGF as novel biomarkers in diagnosis of endometriosis. J Med Biochem. 2016;35(1):63–68.
   PubMed Web of Science ®Google Scholar
• Li YH, Vidakovic S, Milic N, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med. 2008;6(1):1.
   PubMedGoogle Scholar
• Zhang M, Zhang X, Zhao S, et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Target Oncol. 2014;9(4):349–357.
   PubMed Web of Science ®Google Scholar
• Goossens-Beumer IJ, Zeestraten ECM, Benard A, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer. 2014;110(12):2935–2944.
   PubMed Web of Science ®Google Scholar
• Megliorino R, Shi F-D, Peng -X-X, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 2005;29(3):241–248.
   PubMedGoogle Scholar
• Chen P, Zhu J, Liu D-Y, et al. Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med Oncol. 2014;31(1):775.
   PubMed Web of Science ®Google Scholar
• Boidot R, Vegran F, Lizard-Nacol S. Transcriptional regulation of the survivin gene. Mol Biol Rep. 2014;41(1):233–240.
   PubMed Web of Science ®Google Scholar
• Galloway NR, Ball KF, Stiff T, et al. Yin Yang 1 (YY1): regulation of survivin and its role in invasion and metastasis. Crit Rev Oncog. 2017;22(1–2):23–36.
   PubMedGoogle Scholar
• Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67(17):8014–8021.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Yamauchi T, Hiramoto M, et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics. 2012;11(7):M111 013243.
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010;103(1):36–42.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Thomas A, Rajan A, et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(10):2601–2606.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Nishio K, Sakai K, et al. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;86(2):211–219.
   PubMed Web of Science ®Google Scholar
• Hansen JB, Majken Westergaard NF, Kjaerulff LS, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7(9):2736–2745.
   PubMed Web of Science ®Google Scholar
• Eugene Park EJG, Hsieh Y-T, Schaefer P, et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011;8(8):2191–2199.
   Google Scholar
• Raetz EA, Morrison D, Romanos-Sirakis E, et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014;36(6):458–463.
   PubMed Web of Science ®Google Scholar
• Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14(2):120–128.
   PubMed Web of Science ®Google Scholar
• Callies S, André V, Patel B, et al. Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol. 2011;71(3):416–428.
   PubMed Web of Science ®Google Scholar
• Erba HP, Sayar H, Juckett M, et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013;31(4):1023–1034.
   PubMed Web of Science ®Google Scholar
• Ronald Natale FB, Kowalski D, Ramlau R, et al. Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study. J Thorac Oncol. 2014;9(11):1704–1708.
   PubMed Web of Science ®Google Scholar
• Santhi Kondur JC, Baker CH, Safe S, et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther. 2009;8(3):533–542.
   PubMed Web of Science ®Google Scholar
• Hurtado M, Sankpal U, Kaba A, et al. Novel survivin inhibitor for suppressing pancreatic cancer cells growth via downregulating Sp1 and Sp3 transcription factors. Cell Physiol Biochem. 2018;51(4):1894–1907.
   PubMedGoogle Scholar
• Eslin D, Lee C, Sankpal UT, et al. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study. Tumour Biol. 2013;34(5):2781–2789.
   PubMedGoogle Scholar
• Shelake S, Sankpal UT, Eslin D, et al. Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells. Apoptosis. 2019;24(1–2):21–32.
   PubMed Web of Science ®Google Scholar
• Pathi S, Li X, Safe S. Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog. 2014;53(Suppl S1):E53–61.
   PubMedGoogle Scholar
• Esteve PO, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007;282(4):2615–2625.
   PubMed Web of Science ®Google Scholar
• Shelake S, Sankpal UT, Paul Bowman W, et al. Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth. Invest New Drugs. 2017;35(2):158–165.
   PubMed Web of Science ®Google Scholar
• Shim JH, Shin JA, JungJY, et al. Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev. 2011;20(2):102–111.
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Glod J, Peer CJ, et al. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80(3):645–652.
   PubMed Web of Science ®Google Scholar
• Annunziata MC, Stefano AD,Fabbrocini G, et al. Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig. 2019;39(9):825–834.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res. 2020;152:104609.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848.
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA, Figel SA, Jingxin Q, et al. Survivin monoclonal antibodies detect survivin cell surface expression and inhibit tumor growth in vivo. Clin Cancer Res. 2018;24(11):2642–2652.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Karkada M, Oza AM, et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015;4(8):e1026529.
   PubMed Web of Science ®Google Scholar
• Inc., I., Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer. 2020.
   Google Scholar
• Ciesielski MJ, Ahluwalia MS, Munich SA, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010;59(8):1211–1221.
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA, Ciesielski MJ, Jingxin Q, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65(11):1339–1352.
   PubMed Web of Science ®Google Scholar
• Jiang S, Ciesielski MJ, Jingxin Q, et al. Overlapping synthetic peptides as vaccines. Vaccine. 2006;24(37–39):6356–6365.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hai H, Demin L, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. J Biol Chem. 2009;284(14):9184–9191.
   PubMed Web of Science ®Google Scholar
• Lili Cai JZ, Zhu R, Shi W, et al. Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins. Oncotarget. 2017;8(44):76516–76524.
   PubMedGoogle Scholar
• Xu X, Hegazy WAH, Linjie G, et al. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 2014;74(21):6260–6270.
   PubMed Web of Science ®Google Scholar
• Vladimir Pisarev BY, Salup R, Sherman S, et al. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9(17):6523–6533.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu C, Zhang F, et al. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016;34(24):2648–2655.
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Berntsen A, Hadrup SR, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010;12(6):721–734.
   PubMed Web of Science ®Google Scholar
• Uslu U, Erdmann M, Schliep S, et al. Sarcoidosis under dendritic cell vaccination immunotherapy in long-term responding patients with metastatic melanoma. Anticancer Res. 2017;37(6):3243–3248.
   PubMed Web of Science ®Google Scholar